부산대학교 도서관

To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.amjhyper.2007.04.001 Byline: Jean E. Sealey, John H. Laragh Keywords: Aliskiren; renin inhibitor; renin; renin-angiotensin; clinical trial; hypertension; renovascular hypertension; malignant hypertension; angiotensin-converting enzyme inhibitor; angiotensin II type 1 receptor blocker; diuretic Abstract: A review of six clinical trials of aliskiren involving >5,000 patients with mild to moderate hypertension indicated that this first of a new class of orally active antihypertensive drugs is no more effective than angiotensin-converting enzyme inhibitors (CEIs), angiotensin receptor blockers (ARBs), or diuretics for lowering blood pressure. The starting dose is 150 mg; 300 mg is usually more effective, but 600 mg is no better than 300 mg. Aliskiren in combination with a diuretic appeared to lower blood pressure more than an aliskiren-ARB combination, but still failed to control blood pressure ( Author Affiliation: Department of Cardiothoracic Surgery, New York Presbyterian Hospital and Weill Medical College of Cornell University, New York, New York. Article History: Received 21 February 2007; Revised 30 March 2007; Accepted 1 April 2007 Article Note: (footnote) Supported by grants from the Gelb Foundation, New York, NY, the Commonwealth Foundation, New York, NY, and the Rudin Foundation, New York, NY., Potential conflicts of interest: J.E.S. and J.H.L. are consultants for Diasorin, Inc., Stillwater, MN; J.H.L. has licensed US patent 09/657,027, "Method for Evaluating and Treating Hypertension," to Diasorin, Inc., Stillwater, MN; and J.E.S. is a consultant to Daiichi Sankyo, Inc., Parsippany, NJ.